Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 4/20 | 0.51 |
| ▸ | GJB2 | P29033 | 1/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.38 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.38 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.38 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.38 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.38 |
| ▸ | CDC25B | P30305 | 5/20 | 0.37 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26533887 | 0.92 | TACR2 (0.42) | TACR2HTTPKMCSNK1D | |
| SCHEMBL22288945 | 0.76 | TACR2 (0.56) | TACR2NT5EPTPN1PTPN2CDC25B | |
| SCHEMBL26658237 | 0.76 | TACR2 (0.44) | TACR2NT5EPTPN1PTPN2CDC25B | |
| SCHEMBL26658247 | 0.75 | TACR2 (0.44) | TACR2NT5EPTPN1PTPN2SSTR1 | |
| SCHEMBL22288930 | 0.75 | TACR2 (0.54) | TACR2NT5EPTPN1PTPN2CDC25B | |
| SCHEMBL22288928 | 0.75 | TACR2 (0.56) | TACR2NT5EPTPN1PTPN2CDC25B | |
| SCHEMBL278501 | 0.75 | TACR2 (0.54) | TACR2NT5EPTPN1PTPN2SSTR1 | |
| SCHEMBL22704683 | 0.74 | TACR2 (0.45) | TACR2GJB2NT5EPTPN1PTPN2 | |
| SCHEMBL30646414 | 0.74 | TACR2 (0.43) | TACR2NT5EPTPN1PTPN2CDC25B | |
| SCHEMBL22288934 | 0.74 | TACR2 (0.53) | TACR2NT5EPTPN1PTPN2CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20200369711-A1 | MODIFIED CYCLIC DINUCLEOSIDE COMPOUNDS AS STING MODULATORS | ALIGOS THERAPEUTICS, INC. | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369711-A1 | MODIFIED CYCLIC DINUCLEOSIDE COMPOUNDS AS STING MODULATORS | STING1, CGAS, IRF3 | TACR2 4524/4885GJB2 4580/4885NT5E 191/4885 |
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | STING1, CGAS, IRF3 | TACR2 4524/4885GJB2 4580/4885NT5E 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.